BioSpace News Archive

SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that Jens Hennecke, chief business officer of SOTIO, is presenting at BIO-Europe Digital being held on October 26 - 29 , 2020 . The presentation will be made available on demand on the Bio Europe website and accessible to attendees registered for the event. The 26th annual BIO-Europe global life sciences partnering event is

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that one patient‘s experience on the Phase 1 trial of MB-105,

With the high demand for Covid-19 testing, BioLife Sciences (OTCPK: BLFE) is pleased to announce the availability of the FebriDx® - an ultra-rapid, disposable, point-of-care test device that identifies a clinically significant Acute Respiratory Infection (ARI) and differentiates viral from bacterial causes.

Foldax® , Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted approval to expand the U.S. clinical study of the Tria™ surgical aortic heart valve. This next stage of enrollment is expected to begin within the next month. “We are excited to expand enrollment in this U.S. clinical study to gain additional clinical experience with the Tria valve,” stated Frank Shannon, MD, Chief of Cardiov

Sunovion Pharmaceuticals Inc. announced that the company is marking ten years since it was established in October 2010.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of two abstracts featuring data from the Phase 3 program evaluating Sci-B-Vac ® , the company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, in e-poster present

PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar third quarter 2020 financial results by press release on Monday, November 9, 2020 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on November 9, 2020 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-888-599-8688 (U.S. and Canada) or +44 (0)330 33

Meeting outcome confirms the Company’s pathway to a planned MAA submission for Vicineum in early 2021 with anticipated approval in early 2022

The initial six approved formulations were developed to enhance human performance and cognitive health

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has received the second tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.